Clinical trial
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Trial to Compare the Efficacy and Safety of Fixed Doses of SEP-363856 to Placebo in the Treatment of Adults With Generalized Anxiety Disorder
NCT07759128 is registered in ClinicalTrials.gov with Otsuka Pharmaceutical Development & Commercialization, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Trial to Compare the Efficacy and Safety of Fixed Doses of SEP-363856 to Placebo in the Treatment of Adults With Generalized Anxiety Disorder
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- July 28, 2026
- Completion date
- December 13, 2028
- Enrollment
- 576 (estimated)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.